Vox Sanguinis · 2003 · 56 citations · 16 references
PharmacyPharmacologyToxicologyAnalytical ToxicologyBiochemical ToxicologyReproductive ToxicologyHematologic ToxicitySafety PharmacologyGeneral ToxicologyPhotobiological SafetyPhototoxicity AnalysisPlasma MedicinePlasma SafetySafety Profile ReviewUltraviolet Light ExposureUltraviolet Light Treatment
BACKGROUND AND OBJECTIVES: The newly developed INTERCEPT Blood System for plasma uses the addition of a new psoralen, amotosalen HCl (AMOTOSALEN), followed by illumination with ultraviolet A light, to inactivate viruses, bacteria, protozoa and leucocytes that may contaminate fresh-frozen plasma (FFP). Extensive toxicology studies were performed to characterize the safety of the photochemical treatment process for its intended use with plasma. MATERIALS AND METHODS: The studies of general toxicology, safety pharmacology, phototoxicity, reproductive toxicity and venous irritation, summarized in this review, provide a comprehensive toxicology profile for photochemically treated 100% plasma. RESULTS: No specific target organ toxicity (based on clinical or histological pathology), phototoxicity, or reproductive toxicity was observed. CONCLUSIONS: The results of an extensive series of studies have demonstrated no toxicologically relevant effects of photochemically treated 100% plasma prepared using the INTERCEPT Blood System for plasma.
16
The Risk of Transfusion-Transmitted Viral Infections
George B. Schreiber, Michael P. Busch, Steven Kleinman et al. · New England Journal of Medicine · 1996 · 1.9K citations
Spontaneous and carcinogen–induced tumorigenesis in p53–deficient mice
Michele Harvey, Mark J. McArthur, Charles A. Montgomery et al. · Nature Genetics · 1993 · 543 citations
Practice Parameter for the Use of Fresh-Frozen Plasma, Cryoprecipitate, and Platelets
E. Shannon Cooper · JAMA · 1994 · 297 citations
Medicine, Hematology, Pediatrics +17